Dr. John Cush RheumNow
3 years 3 months ago
GCA biopsy: When and How
Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent
@anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side
>1 cm length
#RNL2023 @RheumNow https://t.co/Pn25Qt0WL4 https://t.co/5qROaTbD2w
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.
Dr. John Cush RheumNow
3 years 3 months ago
Dr. Spiera's approach to PMR treatment
- prefers methylprednisolone
- rapid taper over 16 weeks
- consider GC sparing therapy (MTX, IL-6i)
@Rheumnow #RNL2023 https://t.co/LR9e0aXkeN https://t.co/qXUBkz5vfe
Dr. John Cush RheumNow
3 years 3 months ago
SAPHYR, presented at #ACR22, unpublished
Robert Spiera at #RNL2023
Phase 3 study for refractory PMR
Sustained remission of disease, less steroids usage, steroid toxicity, and improved PROs
@RheumNow https://t.co/oQJV7gUV3W https://t.co/S1LRBT55Qn
Next-generation DNA sequencing (NGS) techniques show the presence of bacterial DNA in surgical specimens of hip and knee arthritis, from patients undergoing first-time total joint arthroplasty, reports a study in The Journal of Bone & Joint Surgery.
Dr. John Cush RheumNow
3 years 3 months ago
IL-6 for PMR
SPARE and SEMAPORE (Toci), SAPHYR (Sari)
2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off
Robert Spiera @RheumNow #RNL2023 https://t.co/VtzW01Ez7D https://t.co/P6oUQvmDXH
Dr. John Cush RheumNow
3 years 3 months ago
Swedish registry review of #MTX initiation in early #PsA vs #RA (n 3642each). 2 years after MTX start, 71% of PsA vs 76% of patients with RA remained on MTX & the majority (66%/60%) had not started another DMARD, or a biologic (77%/74%) https://t.co/nTJO04sn65 https://t.co/gLjKzj2c74
Dr. John Cush RheumNow
3 years 3 months ago
Evidence-Based Guidelines for EGPA
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, affecting between 10 and 14 cases per million globally.
https://t.co/VixECcPv4R https://t.co/XgEHRgDiPj
Dr. John Cush RheumNow
3 years 3 months ago
RELIEF Trial: Sublingual Cyclobenzaprine in Fibromyalgia
https://t.co/a6KUPcfmxM https://t.co/ToRJQVsZSu
Dr. John Cush RheumNow
3 years 3 months ago
RCT of 122 active plaque Psoriasis pts (38F, 55M) with low vitamin D (~15). Rx w/ either PBO or Vit D (100K IU, followed by 20K IU/wk x 4 mos). Vitamin D supplementation had no effect on psoriasis severity (but pts had mild PSO). https://t.co/JXtEBaop3c https://t.co/ScGtBUIrm0
Dr. John Cush RheumNow
3 years 3 months ago
Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK "at-risk" population are patients Age ≥65 years or ever smoker who exhibited the excess adverse events (malignancies, MACE, MI, VTE, all-cause death) comparedd to TNFi (HRs 1.41–5.19) https://t.co/k78WsPR1Mv https://t.co/JmTDSctIa0
Peresolimab is a humanized IgG1 monoclonal antibody that acts as a programmed cell death protein 1 (PD-1) agonist (stimulator). The NEJM reports that PER met its efficacy primary endpont in treating patients with active rheumatoid arthritis (RA).
